Literature DB >> 21122568

Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease.

Kuldeep Cheent1, Jonathan Nolan, Sohail Shariq, Liina Kiho, Arabinda Pal, Jayantha Arnold.   

Abstract

We present the case of a 28 year old lady with refractory Crohn's Disease treated with infliximab throughout her pregnancy. Her baby was born healthy and received a Bacillus Calmette-Guérin (BCG) vaccine aged 3 months. Soon after this the infant became unwell and died aged 4.5 months. At post-mortem the cause of death was attributed to an unusual complication of the BCG vaccine, known as disseminated BCG. BCG vaccination is contraindicated in individuals who are receiving immunosuppressive drugs. We recommend physicians should exercise caution before such vaccines are used in infants born to mothers taking anti-TNF therapies or other potentially immunosuppressive IgG1 antibodies.
Copyright © 2010 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21122568     DOI: 10.1016/j.crohns.2010.05.001

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  63 in total

Review 1.  IBD in 2010: optimizing treatment and minimizing adverse events.

Authors:  Bénédicte De Vroey; Jean-Frédéric Colombel
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

Review 2.  From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease.

Authors:  Charles W Randall; John A Vizuete; Nicholas Martinez; John J Alvarez; Karthik V Garapati; Mazyar Malakouti; Carlo M Taboada
Journal:  Therap Adv Gastroenterol       Date:  2015-05       Impact factor: 4.409

3.  Managing Crohn's Disease during Pregnancy.

Authors:  Brîndusa Ana Cimpoca; Florina Nedelea; Mirona Furtuna; Gheorghe Peltecu; Anca Maria Panaitescu
Journal:  Maedica (Bucur)       Date:  2016-09

Review 4.  [Dermatological topical and systemic therapy during pregnancy].

Authors:  S Grunewald; P Staubach
Journal:  Hautarzt       Date:  2017-02       Impact factor: 0.751

5.  Vaccination issues in patients with inflammatory bowel disease receiving immunosuppression.

Authors:  Seper Dezfoli; Gil Y Melmed
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-08

Review 6.  Preventing infective complications in inflammatory bowel disease.

Authors:  Justine Mill; Ian C Lawrance
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

7.  Evidence-based clinical practice guidelines for inflammatory bowel disease.

Authors:  Katsuyoshi Matsuoka; Taku Kobayashi; Fumiaki Ueno; Toshiyuki Matsui; Fumihito Hirai; Nagamu Inoue; Jun Kato; Kenji Kobayashi; Kiyonori Kobayashi; Kazutaka Koganei; Reiko Kunisaki; Satoshi Motoya; Masakazu Nagahori; Hiroshi Nakase; Fumio Omata; Masayuki Saruta; Toshiaki Watanabe; Toshiaki Tanaka; Takanori Kanai; Yoshinori Noguchi; Ken-Ichi Takahashi; Kenji Watanabe; Toshifumi Hibi; Yasuo Suzuki; Mamoru Watanabe; Kentaro Sugano; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2018-02-10       Impact factor: 7.527

Review 8.  The use of biologics for autoimmune rheumatic diseases in fertility and pregnancy.

Authors:  May Ching Soh; Marcelo Moretto
Journal:  Obstet Med       Date:  2019-05-30

9.  Safety of Tumor Necrosis Factor Inhibitors during Pregnancy and Breastfeeding.

Authors:  Harish Raja; Eric L Matteson; Clement J Michet; Justine R Smith; Jose S Pulido
Journal:  Transl Vis Sci Technol       Date:  2012-09-21       Impact factor: 3.283

Review 10.  Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review.

Authors:  Renée M Marchioni; Gary R Lichtenstein
Journal:  World J Gastroenterol       Date:  2013-05-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.